Daniel Albertson, MD

Associate Professor (Clinical), University of Utah School of Medicine

Specialties

• Fish Pathology
• Breast
• Sarcoma pathology
• Genitourinary pathology
• Gynecologic pathology

Education

• Medical Degree—University of Nebraska
• Residency—Anatomic and Clinical Pathology, Creighton University
• Fellowship—Surgical Pathology, University of Utah

Certification/Affiliations

• United States and Canadian Academy of Pathology
• College of American Pathologists

Research Interests

• Oncologic genitourinary and gynecologic pathology
• Solid tumor FISH pathology
• Applications of digital pathology

Awards

• Hal Lankford Pathology Resident Award, University of Nebraska, 2011
• Outstanding Teaching Award in Anatomic Pathology, University of Utah, 2017
• The Joe Holden Award for Clinical Excellence in Anatomic Pathology, 2018

Recent Publications

• Stenehjem DD, et al. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One. 2019;14(1):e0210415
• Gupta S, et al. Histone deacetylase inhibition has targeted clinical benefit in ARID1A-mutated advanced urothelial carcinoma. Mol Cancer Ther. 2019;18(1):185–95.
• Tward JD, et al. Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med. 2018;7(12):6030–9.
• Gupta S, et al. Comprehensive genomic sequencing of urothelial tumors identifies rare SMARCB1 (INI-1)-deficient carcinomas of the urinary system. Clin Genitourin Cancer. 2018;16(2):e373–82.
• Kuzman JA, et al. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol. 2017;17(1):1.